Pfizer has no plans to manufacture its COVID – 19 vaccine in India and keep the supply lines limited to the US and Europe:
Pfizer has recently made an announcement regarding its vaccine production on 11 March 2021. It stated that it does not plan to manufacture the COVID – 19 vaccine in India during this pandemic. It also expressed its desire to keep the supply lines limited to the US and Europe. 1
Pfizer COVID –19 vaccine: The background check
Per media reports, the pharma company told the Indian government on 10 March 2021 about its decision to manufacture the vaccines locally. This, however, will happen if it gets faster regulator clearance and freedom on pricing and exports.
Pfizer has established two dedicated supply lines for the vaccine till now. One is in the United States, and the other is in Europe. These lines are for the exclusive manufacturing of vaccines for use across the globe. The company announced that this would be its supply strategy, and it has no plans to expand this for now.
However, Pfizer plans to explore other opportunities once the pandemic phase is over. Pfizer and BioNTech also announced that its vaccine is 94 % effective in preventing asymptomatic infections. This is based on the data from Israel and was declared on 10 March 2021. These results imply that the vaccine can reduce the transmission of the virus. It also revealed that unvaccinated individuals were 44 times more likely to develop symptomatic COVID – 19. Similarly, these individuals were 29 times more likely to die from the disease than the vaccinated individuals.
Pfizer is the first company to apply for regulatory approval in India for Pfizer COVID –19 vaccine. However, the country’s drug regulator had requested the company to conduct clinical studies on the Indian population. India put this request forth to establish the vaccine’s safety and immune response. But, Pfizer pulled out its application on receiving this response.
The company plans to ensure equitable and affordable access to its COVID – 19 vaccine to everyone globally, including in India. Read COVID Vaccination Program in India.
- Pharma News – 23.01.2023 to 29.01.2023Mankind Pharma invests in Actimed Therapeutics to support the latter’s development of treatment for cancer cachexia. On 23 January 2023, …
- Lupin issues nationwide recall of Clobetasol propionate cream.On 4 February 2023, Lupin announced the recall of Clobetasol propionate cream over quality issues. As per the USFDA [1], the pharma …
Lupin issues nationwide recall of Clobetasol propionate cream. Read More »
- Global Pharma Healthcare recalls Artificial Tears Lubricant eye drops.The USFDA[1] has revealed that Global Pharma Healthcare recalls all the batches of artificial tears lubricant eye drops from the …
Global Pharma Healthcare recalls Artificial Tears Lubricant eye drops. Read More »
- Milestones in Cancer Research and DiscoveryCancer research and discovery is the process of uncovering new information about cancer and how it can be treated. This …
- OAI notice for Torrent Pharma Indrad facilityUSFDA issues OAI notice for Torrent Pharma’s Indrad facility in Gujarat.In response to this notice, Torrent Pharma has clarified that …
- Cancer Cachexia: Mankind Pharma’s association with Actimed TherapeuticsOn 23 January 2023, Mankind Pharma announced its move to invest in the UK-based clinical-stage specialty pharma company Actimed Therapeutics. …
Cancer Cachexia: Mankind Pharma’s association with Actimed Therapeutics Read More »
Pingback: Pfizer to supply COVID vaccine to India > PharmaCampus